SeekingAlpha · Aug 18, 2026
CONMED Corporation: Organic Growth Is Masked By Divestitures
Conmed's headline growth appeared flat at $343 million in the last quarter, but organic growth actually increased by 6%, with the leading segment being the...
CN
NYSE · CNMD
CONMED Corporation
Healthcare · Medical - Devices
$49.26
Up+$0.01 (+0.02%)
Updated Aug 19, 2026, 7:59 AM
SID Score
6.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.23B
- P/E ratio
- 11.17
- Dividend yield
- 1.62%
- 52-week range
- $31.44 – $56.64
- Volume
- 498.56K
- Avg. volume
- 469.39K
Price performance
CNMD price history
1M range · 21 trading sessions · Daily adjusted prices
CNMD closed at $49.26 after 21 trading sessions, up 17.62% for the selected period.
- Last close
- $49.26
- Period change
- +17.62%
- Period low
- $41.27
- Period high
- $51.86
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 18, 2026 | $50.05 | $50.95 | $49.23 | $49.26 | 498.56K |
| Aug 17, 2026 | $49.05 | $49.93 | $48.935 | $49.25 | 453.11K |
| Aug 14, 2026 | $49.60 | $50.59 | $49.13 | $50.41 | 232.91K |
| Aug 13, 2026 | $49.81 | $50.39 | $49.115 | $49.82 | 219.95K |
| Aug 12, 2026 | $49.96 | $49.96 | $48.41 | $49.48 | 396.29K |
| Aug 11, 2026 | $49.45 | $50.41 | $49.45 | $49.58 | 239.8K |
| Aug 10, 2026 | $48.64 | $50.1799 | $48.64 | $49.46 | 381.76K |
| Aug 7, 2026 | $49.94 | $50.30 | $48.495 | $49.12 | 434.42K |
| Aug 6, 2026 | $49.60 | $50.42 | $48.80 | $49.77 | 536.1K |
| Aug 5, 2026 | $50.98 | $50.98 | $48.84 | $49.30 | 431.19K |
| Aug 4, 2026 | $52.05 | $52.05 | $50.04 | $50.40 | 561.61K |
| Aug 3, 2026 | $47.42 | $53.66 | $47.42 | $51.86 | 1.2M |
| Jul 31, 2026 | $45.60 | $46.78 | $45.24 | $46.30 | 641.52K |
| Jul 30, 2026 | $47.49 | $49.00 | $45.95 | $46.98 | 850.44K |
| Jul 29, 2026 | $44.69 | $44.69 | $42.70 | $43.21 | 763.11K |
| Jul 28, 2026 | $44.45 | $46.4867 | $44.12 | $44.25 | 762.8K |
| Jul 27, 2026 | $43.47 | $44.00 | $42.87 | $43.51 | 437.72K |
| Jul 24, 2026 | $41.80 | $43.76 | $41.80 | $42.68 | 434.87K |
| Jul 23, 2026 | $41.72 | $42.38 | $40.985 | $41.27 | 690.36K |
| Jul 22, 2026 | $42.36 | $42.715 | $41.24 | $42.00 | 636.44K |
| Jul 21, 2026 | $42.62 | $44.065 | $41.745 | $41.88 | 611.44K |
Latest CNMD news
The latest Smart Investors Daily articles mentioning CNMD.
Stock researchCompany · Overview
CNMD research
Overview
Company profile and research snapshot.
Company profile
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Geographically operates in USA, Europe, Middle East & Africa, Asia Pacific and North America. Majority is revenue is from USA.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $78.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 30, 2026 | Wells Fargo | Equal-Weight | — |
| Jul 30, 2026 | Piper Sandler | Neutral | — |
| Jul 9, 2026 | BMO Capital | Market Perform | — |
| Jun 29, 2026 | B of A Securities | Underperform | — |
| May 18, 2026 | B of A Securities | Neutral | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Jul 31, 2026
CONMED Corporation 2026 Q2 - Results - Earnings Call Presentation
2026-07-31. The following slide deck was published by CONMED Corporation in conjunction with their 2026 Q2 earnings call.
Benzinga · Jul 30, 2026
Piper Sandler Reiterates Neutral on Conmed, Raises Price Target to $45
Piper Sandler analyst Matt O'Brien reiterates Conmed (NYSE:CNMD) with a Neutral and raises the price target from $39 to $45.
Benzinga · Jul 30, 2026
Wells Fargo Maintains Equal-Weight on Conmed, Raises Price Target to $46
Wells Fargo analyst Larry Biegelsen maintains Conmed (NYSE:CNMD) with a Equal-Weight and raises the price target from $39 to $46.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
